The company's shares fell by as much as 14.5% in pre-market trading Friday morning in response to the biotech's decision to discontinue the clinical program for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin (AATD). AATD is an inherited condition that results in a misfolded AAT protein in the blood.
Full Answer
Why is Vertex Pharmaceuticals stock down 8% over the last 5 days?
The stock price of Vertex Pharmaceuticals (NASDAQ: VRTX) has seen an 8.1% drop over the last five trading days, after the company announced that it will discontinue the clinical trials for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin (AATD).
When is Vertex Pharmaceuticals'next quarterly earnings announcement?
Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022. View our earnings forecast for Vertex Pharmaceuticals. How were Vertex Pharmaceuticals' earnings last quarter?
What is the upside for Vertex Pharmaceuticals (VRTX) stock?
On average, they anticipate Vertex Pharmaceuticals' stock price to reach $214.88 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.
Where is Vertex Pharmaceuticals located?
Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210. How can I contact Vertex Pharmaceuticals? Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at [email protected], or via fax at 617-576-2109.
See more
Why is the vertex falling?
Vertex Pharmaceuticals in Boston, Massachusetts.
Will Vertex stock recover?
Based on our forecasts, a long-term increase is expected, the "VRTX" stock price prognosis for 2027-05-21 is 345.004 USD. With a 5-year investment, the revenue is expected to be around +26.02%. Your current $100 investment may be up to $126.02 in 2027. Get It Now!
Is Vertex Pharmaceuticals A Good Investment?
In this defensive sector, Vertex Pharmaceuticals Incorporated VRTX is a good stock to own. There are several reasons to own the stock. Good Rank and Rising Estimates: Vertex has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Is Vertex a buy or sell?
Vertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 11 buy ratings, 8 hold ratings, and no sell ratings.
Is Vertex a buy Zacks?
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return5Strong Sell2.83%S&P50011.24%4 more rows
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 113.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +76.65% increase from the last price of 64.25.
Who bought Vertex?
Wind Point PartnersChicago, IL, September 2, 2021 – Wind Point Partners (“Wind Point”), a Chicago-based private equity firm, has acquired The Vertex Companies, Inc.
Is AMD a buy Zacks?
It's calculated as earnings divided by price. For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Why Vertex stock is up?
Vertex Pharmaceuticals (VRTX) issued a bullish 2022 outlook Thursday, leading VRTX stock to approach a 12-month high. The company expects its cystic fibrosis treatments to generate $8.4 billion to $8.6 billion in sales this year. The guidance was well above analyst forecasts for $8.2 billion in sales.
What is VRTX price target?
Stock Price Target VRTXHigh$368.00Median$288.00Low$240.00Average$293.05Current Price$273.73
What sector is Vertex Pharmaceuticals in?
healthcare sectorVertex Pharmaceuticals serves healthcare sector worldwide.
Is Vertex Pharmaceuticals a buy right now?
18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 h...
When is Vertex Pharmaceuticals' next earnings date?
Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast f...
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Thursday, May, 5th. The pharmaceutical company reported...
What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?
Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of for the period....
What price target have analysts set for VRTX?
18 brokerages have issued 12-month target prices for Vertex Pharmaceuticals' stock. Their forecasts range from $210.00 to $350.00. On average, they...
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the following people: Dr. Jeffrey Marc Leiden M.D. , Ph.D., Exec. Chairman (Age 66, Pay $281.98...
What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?
31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com . Reshma Kewalramani has an approval rating of 76% among Ve...
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) , Bi...
What other stocks do shareholders of Vertex Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA)...
What happens if you buy Vertex Pharmaceuticals?
Answer: If you buy and hold Vertex Pharmaceuticals stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong.
What is the Vertex drug?
Vertex’s current commercial drugs primarily deal with Cystic Fibrosis (CF), a genetic disease that affects the lungs and digestive system. While Trifkafta is expected to be the single biggest revenue driver for the next few years, investors are also concerned about the company’s future outside of CF.
How much will Vertex grow in 2021?
However, going by the numbers, Vertex’s revenues are estimated to grow 12% in 2021 as well as 2022, while EPS on an adjusted basis is expected to grow to $13.10 in 2022, compared to $10.32 in 2020.
Will VRTX rebound?
Now that VRTX stock has fallen 8.1% in just five days, will it resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? Going by the historical performance of VRTX stock, it appears that the stock will rebound in the near term. Using the recent trend (8.1% fall in a week) and ten years of historical stock data, the Trefis AI engine finds that VRTX stock will likely move by over 3% over the next one month (twenty-one trading days).
When did VX 814 stop?
Firstly, in mid-October 2020, the company discontinued VX-814, a drug that was being investigated for a potential treatment for alpha-1 antitrypsin deficiency (AATD). This development caused a large 20% hit to the stock in a single trading session.
Is VRTX better than Case 1?
VRTX stock fares better after Case 1, with an average return of 3.4% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 0.3% for Case 2.
Is the P/E multiple 20x?
Despite the strong fundamentals, the company’s P/E multiple didn’t see much growth, rising from 20x in 2018 to 23x in 2020. The P/E multiple is currently back at 20x, which we believe is low and compares with levels of 23x seen as recently as late 2020.
When will Vertex Pharmaceuticals buy back its stock?
How will Vertex Pharmaceuticals' stock buyback program work? Vertex Pharmaceuticals declared that its board has approved a stock repurchase program on Wednesday, July 31st 2019 , which authorizes the company to buyback $500,000,000.00 in shares, according to EventVestor.
What is the NASDAQ symbol for Vertex Pharmaceuticals?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
How much does Vertex Pharmaceuticals make?
Vertex Pharmaceuticals has a market capitalization of $51.90 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.
What is the official website of Vertex Pharmaceuticals?
The official website for Vertex Pharmaceuticals is www.vrtx.com.
What is Vertex Pharmaceuticals?
Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay a dividend.
Why did the AAT trial stop?
The company said it put a stop to the trial after 28 days of administering treatment to patients with alpha-1 antitrypsin deficiency (AAT), because several patients showed high levels of certain liver enzymes.
Is Vertex Pharmaceuticals stock sinking?
Vertex Pharmaceuticals stock was sinking Thursday morning, after the company said it was pulling the plug on a treatment some saw as a “crown jewel” in its pulmonary-drug portfolio.
Is the discontinuation of VX-814 a negative?
Even bulls were taken aback by the news. “The discontinuation of VX-814 due to safety…issues is certainly a negative surprise and is likely to put meaningful pressure on Vertex shares, especially given management's consistently bullish commentary surrounding the program,” Stifel analyst Paul Matteis wrote. He has a Buy rating and $309 price target on the stock.
What is Vertex Pharmaceuticals?
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their CFT... Read more
What is the price target for VRTX in 2021?
On Nov 18, 2021 "Piper Sandler" gave "" rating for VRTX. The price target was changed from $184.00 to 2.3% .
Is Vertex Pharmaceuticals Incorporated stock A Buy?
The Vertex Pharmaceuticals Incorporated stock holds several negative signals and despite the positive trend, we believe Vertex Pharmaceuticals Incorporated will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.
What is the Vertex drug?
Vertex’s current commercial drugs primarily deal with Cystic Fibrosis, a genetic disease that affects the lungs and digestive system. While Trifkafta is expected to be the single biggest revenue driver for the next few years, investors are also concerned about the company’s future outside of CF.
When did VX 814 stop?
Firstly, in mid-October 2020, the company discontinued VX-814, a drug that was being investigated for a potential treatment for alpha-1 antitrypsin deficiency. This development caused a large 20% hit to the stock in a single trading session.
Is the P/E multiple 20x?
Despite the strong fundamentals, the company’s P/E multiple didn’t see much growth, rising from 20x in 2018 to 23x in 2020. The P/E multiple is currently back at 20x, which we believe is low and compares with levels of 23x seen as recently as late 2020.
Is VRTX stock undervalued?
Finally, looking at the valuation, we believe that VRTX stock is undervalued at the current levels of $215. Currently, investors seem to be worried about the pipeline and revenue dependency only on CF drugs. However, going by the numbers, Vertex’s revenues are estimated to grow 12% in 2021 as well as 2022, while EPS on an adjusted basis is expected to grow to $13.10 in 2022, compared to $10.32 in 2020. At the current price of $215, VRTX stock is trading at 19x its 2021 and 16x its 2022 earnings, compared to levels of 23x seen as recently as late 2020, implying that VRTX stock is undervalued currently.
